Lesson plan

2CB7

2CB7, also known as 2C-B-5-hemiFLY-β7, is a serotonin receptor modulator of the phenethylamine, 2C, and benzofuran families related to 2C-B. It is a cyclized phenethylamine or conformationally restrained derivative of 2C-B in which the 5-methoxy group has been cyclized into a dihydrofuran ring and the β position has been connected with the dihydrofuran ring via a propyl group to form a cycloheptane ring to form a tricyclic structure. The compound has syn and anti stereoisomers, with these isomers also being racemic mixtures of (+)- and (–)- enantiomers. The isomers of 2CB7 show affinity for the serotonin 5-HT 2A receptor, with values (K i ) of 74 to 170 nM for syn-2CB7 and 170 to 200 nM for anti-2CB7. These affinities were dramatically lower than those of 2C-B (K i = 0.66–0.88 nM). 2CB7 was first described in the scientific literature by Michael Robert Braden and David E. Nichols and colleagues in 2006. It was developed as part of scientific research into serotonin 5-HT 2A receptor ligand interactions.

Back to article

Article summary

2CB7, also known as 2C-B-5-hemiFLY-β7, is a serotonin receptor modulator of the phenethylamine, 2C, and benzofuran families related to 2C-B. It is a cyclized phenethylamine or conformationally restrained derivative of 2C-B in which the 5-methoxy group has been cyclized into a dihydrofuran ring and the β position has been connected with the dihydrofuran ring via a propyl group to form a cycloheptane ring to form a tricyclic structure. The compound has syn and anti stereoisomers, with these isomers also being racemic mixtures of (+)- and (–)- enantiomers. The isomers of 2CB7 show affinity for the serotonin 5-HT 2A receptor, with values (K i ) of 74 to 170 nM for syn-2CB7 and 170 to 200 nM for anti-2CB7. These affinities were dramatically lower than those of 2C-B (K i = 0.66–0.88 nM). 2CB7 was first described in the scientific literature by Michael Robert Braden and David E. Nichols and colleagues in 2006. It was developed as part of scientific research into serotonin 5-HT 2A receptor ligand interactions.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.